display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - triple negative
es-BC - TNBC - NA - all population
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment ALEXANDRA/IMpassion-030
atezolizumab plus carboplatin plus nab-paclitaxel NeoTRIPaPDLA
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide IMpassion-031 ...
durvalumab based treatment
durvalumab alone GeparNuevo
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-522

Study type: